
A recent study sheds light on potential biomarkers predicting the response to Imatinib therapy in CML patients. Identifying 16 miRNAs associated with imatinib nonresponse, researchers trained a machine learning model, highlighting a multivariable panel combining miRNAs and clinical features as most effective. This panel, exhibiting high predictive performance, promises optimized treatment plans for CML patients, minimizing the risk of relapse. The findings emphasize the significance of personalized treatment strategies in managing CML, raising hope for enhanced patient outcomes.
Like
Save
Share